Caris Life Sciences, 6655 North MacArthur Blvd., 3rd Floor, Irving, TX 75039, USA.
Clin Exp Metastasis. 2012 Oct;29(7):653-5. doi: 10.1007/s10585-012-9483-3. Epub 2012 Jun 8.
The pace of genomic discoveries in the field of cancer is revolutionizing our understanding of the biological dynamics of cancerous growth and, at the same time, fueling research for newer and smarter cancer therapies to reverse the effects of these alterations. These dynamics are driving a tremendous paradigm shift in cancer diagnostics, drug development and clinical trial design with the hope of eliminating the current structure and approach of cancer care, to one which is driven by the underlying biology of the tumor and, thus highly personalized. Much of this paradigm shift has been fueled by the current availability of novel technologies, platforms and bioinformatic tools. Today, therapies are being rationally designed to target the precise genetic alterations with better clinical outcomes with reduced morbidity. Therefore, molecular profiling of tumors to identify the multiplicity of alterations in a tumor is an essential and necessary companion for targeted therapies.
癌症领域的基因组学发现的步伐正在彻底改变我们对癌症生长的生物学动态的理解,同时也推动了针对这些改变的更新、更智能的癌症治疗方法的研究,以逆转这些改变的影响。这些动态正在推动癌症诊断、药物开发和临床试验设计的巨大范式转变,希望消除当前以肿瘤基础生物学为驱动的癌症治疗的结构和方法,从而实现高度个性化。这种范式转变在很大程度上是由当前新型技术、平台和生物信息学工具的可用性所推动的。如今,治疗方法正在被合理设计,以针对特定的基因改变进行靶向治疗,从而获得更好的临床效果,降低发病率。因此,对肿瘤进行分子谱分析以确定肿瘤中多种改变是靶向治疗的必要伴随手段。